- Home
- CARS vs CVAC Comparison
CARS vs CVAC Comparison
Compare CARS & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARS
- CVAC
- Stock Information
- Founded
- CARS 1998
- CVAC 2000
- Country
- CARS United States
- CVAC Germany
- Employees
- CARS N/A
- CVAC N/A
- Industry
- CARS Motor Vehicles
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- CARS Consumer Discretionary
- CVAC Health Care
- Exchange
- CARS Nasdaq
- CVAC Nasdaq
- Market Cap
- CARS 741.3M
- CVAC 818.8M
- IPO Year
- CARS 2017
- CVAC 2020
- Fundamental
- Price
- CARS $11.38
- CVAC $2.72
- Analyst Decision
- CARS Buy
- CVAC Hold
- Analyst Count
- CARS 5
- CVAC 3
- Target Price
- CARS $19.90
- CVAC $10.00
- AVG Volume (30 Days)
- CARS 938.6K
- CVAC 634.5K
- Earning Date
- CARS 05-08-2025
- CVAC 05-22-2025
- Dividend Yield
- CARS N/A
- CVAC N/A
- EPS Growth
- CARS N/A
- CVAC N/A
- EPS
- CARS 0.72
- CVAC N/A
- Revenue
- CARS $719,152,000.00
- CVAC $70,565,734.00
- Revenue This Year
- CARS $5.81
- CVAC $742.57
- Revenue Next Year
- CARS $4.69
- CVAC N/A
- P/E Ratio
- CARS $15.78
- CVAC N/A
- Revenue Growth
- CARS 4.35
- CVAC 75.11
- 52 Week Low
- CARS $10.80
- CVAC $2.22
- 52 Week High
- CARS $21.24
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- CARS 36.25
- CVAC 36.80
- Support Level
- CARS $10.87
- CVAC $2.78
- Resistance Level
- CARS $12.51
- CVAC $3.33
- Average True Range (ATR)
- CARS 0.50
- CVAC 0.15
- MACD
- CARS 0.17
- CVAC -0.01
- Stochastic Oscillator
- CARS 33.63
- CVAC 1.61
About CARS Cars.com Inc.
Cars.com Inc is an online destination for buying and selling new and used vehicles. It is an audience-driven technology company empowering the automotive industry. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.